Munich (Germany), August 9, 2019: ImevaX GmbH, a specialist in rapid diagnostic tests and a vaccine against Helicobacter pylori (H. pylori), announces today the completion of a EUR 2.5 million Series A-2 financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund, Santo Venture Capital and KfW. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been recently awarded a EUR 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF).
The funds will be used to focus on development of a rapid diagmostic test for detection of Helicobacter pylori (H. pylori) to market entry and to partner IMX101 with results from the clinical study phase.
Dr. James Neil Phillips, Chief Executive Officer of ImevaX GmbH since September 16, 2018 commented: “The business development potential for both the vaccine IMD101and the diagnostic test IMD101 are promising. In particular our diagnostic test for the detetction of Helicobacter pylori (H. pylori) gets a lot of response in the Asian markets .”
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines and develop new generations of rapid diagnostic tests.
About Wellington Partners
Wellington Partners is one of the most successful pan-European venture capital firms. With some EUR 850 million under management and offices in London, Munich, Palo Alto and Zurich, the firm invests into companies throughout Europe that have the potential to become global leaders in the areas of Life Sciences, Digital Media and Software. Since 1998, Wellington Partners has invested in more than 100 European companies, including now publicly traded Actelion, Evolva, Genticel, Implanet, Oxford Immunotec, Supersonic Imagine and privately held companies like AyoxxA, immatics, invendo medical, MPM Medical, MTM Laboratories (acquired by Roche), NEUWAY Pharma, Oxagen, Rigontec, Quanta, Sapiens (acquired by Medtronic), Sensimed and Symetis.
BioMedPartners AG is an independent healthcare-dedicated investment firm based in Basel, Switzerland, that provides private equity and mezzanine financing to private early- to mid-stage healthcare and life science companies in Switzerland and neighboring regions (Alpine Rim). BioMedPartners have over CHF 250 million under management and have invested in or given loans to 45 companies, including now publicly traded Affimed, Arpida, Evolva and Santhera and the exited privately held companies Glycart Biotechnologies (acquired by Roche), ESBATech (acquired by Alcon/Novartis), Activaero (acquired by Vectura) and Okairos (acquired by GSK). BioMedPartners currently invest out of their BioMedInvest II LP fund, which has a size of CHF 106 million, and was closed in 2009.
Since its foundation in 1948, KfW has become one of the World’s leading promotional banks. KfW Group supports change and encourages forward-looking ideas in Germany, Europe and throughout the world. In 2014, KfW Group committed to a total EUR 74.1 billion of investments, focusing mainly on small and medium-sized businesses, environmental and climate protection.
About Santo Venture Capital
Santo Venture Capital is the venture arm of ATHOS Service GmbH, the Family Office of the Strüngmann family.
For further information, please contact:
Chief Financial Officer
Tel: +49 (0) 89-41 424 55-0